Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24197470 | 0.90 | MAPT (0.33) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL25569463 | 0.89 | KDM4E (0.33) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL25569465 | 0.88 | LMNA (0.32) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL25569475 | 0.88 | HDAC1 (0.32) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL25569502 | 0.85 | — | — | |
| SCHEMBL24197474 | 0.84 | CHRNA1 (0.34) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL25569466 | 0.83 | KDM4E (0.32) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL25569468 | 0.82 | KDM4E (0.32) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL24197468 | 0.81 | MAPT (0.34) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL25569467 | 0.81 | LMNA (0.32) | KDM4ENPC1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | KDM4E 2362/4885NPC1 1609/4885ALDH1A1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.